Gurobi 9.5 Delivers Enterprise Features and Even Better Performance
Gurobi Optimization, LLC, creator of the world’s fastest mathematical optimization solver, today announced the release of Gurobi Optimizer 9.5. This release provides customers with an even faster compute engine, with impressive performance improvements across all supported problem types.
Gurobi 9.5 also includes new features that make it well suited for enterprise use, including:
- Seamless Docker Deployments: Run Gurobi in container environments, easily, with the Gurobi Web License Service (WLS).
- User-Level Management: Manage users and assign permission levels in a centralized location, by integrating Gurobi Compute Server and Cluster Manager with LDAP repositories.
- Better API Key Management: Label API keys with descriptive information in the Cluster Manager to simplify API key tracking and management.
Customers will discover over a dozen enhancements across the product, such as native support for Apple M1, powerful new heuristics for non-convex quadratic models, norm constraints, deterministic work measures, memory limit parameters, and more user control of IIS computation, as well as improvements to callbacks and tuning.
“I’m confident that our customers will be really pleased with Gurobi 9.5. And happy customers are the foundation upon which our whole business is built,” said Dr. Edward Rothberg, Chief Executive Officer and Co-founder of Gurobi Optimization.
Gurobi 9.5 also showcases the company’s continued support for Python—the most popular programming language in the world—with an improved Python interface and support for Python 3.10.
“One of the most challenging parts of running a modern business is managing complexity. Every decision you make affects other decisions. With Gurobi Optimizer, you can explore all the possibilities and all the implications—and identify your best course of action, in seconds,” added Dr. Rothberg.
“Even though the Gurobi Optimizer is the fastest mathematical optimizer in the world, we’re not going to rest on our laurels. We will keep pushing to improve and innovate because we’re passionate about mathematical optimization and the difference it makes in solving real-world problems,” said Dr. Tobias Achterberg, Vice President of Research and Development (R&D) at Gurobi Optimization.
The team’s commitment to continual improvement is evident in the performance numbers. Gurobi Optimizer 9.5 has boosted its speeds across the board, including:
- Primal Simplex: 23% faster overall, 43% faster on hard models
- Dual Simplex: 20% faster overall, 43% faster on hard models
- Barrier: 18% faster overall, 56% faster on hard models
- Concurrent LP: 14% faster overall, 54% faster on hard models
- MIP: 15% faster overall, 27% faster on hard models
- Convex MIQP: 30% faster overall, 68% faster on hard models
- Convex MIQCP: 33% faster overall, 78% faster on hard models
- Non-Convex MIQCP: 3.0x faster overall, 7.5x faster on hard models
“Our customers rely on us for solving extremely complex challenges. Our technology makes that possible. But our secret sauce is our team of specialists and PhDs, as well as our partner network. These are the people who make Gurobi come to life—working closely with our customers and helping them succeed,” added Dr. Achterberg.
To learn more about Gurobi 9.5, please visit https://www.gurobi.com/9.5.
About Gurobi Optimization
Gurobi produces the world’s fastest and most powerful mathematical optimization solver – the Gurobi Optimizer – which is used by leading global companies across more than 40 different industries to rapidly solve their complex, real-world problems and make automated decisions that optimize their efficiency and profitability. As the market leader in mathematical optimization software, we aim to deliver not only the best solver, but also the best support – so that companies can fully leverage the power of mathematical optimization (on its own or in combination with other AI techniques such as machine learning) to drive optimal business decisions and outcomes.
Founded in 2008, Gurobi has operations across the USA, Europe, and Asia and has more than 2,500 customers globally including SAP, Air France, Uber, and the National Football League (NFL). For more information, please visit https://www.gurobi.com/ or call +1 713 871 9341.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005125/en/
Contact information
Nell-Marie Colman
(540) 952 9719
Gurobi Optimization
colman@gurobi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
